

- 151. (New) The method of any of claim 147, 148, 149 or 150, wherein the human Y4 receptor has an amino acid sequence substantially identical to the amino acid sequence shown in Figure 1 (SEQ ID NO.2).--
- 152. (New) The method of any of claim 147, 148, 149 or 150, wherein the human Y4 receptor is encoded by a nucleic acid sequence identical to the receptor-encoding nucleic acid sequence contained in plasmid pcEXV-Y4 (ATCC Accession No. 75631).--
- 153. (New) The method of any of claim 147, 148, 149 or 150, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.--

REMARKS

Claims 1-146 were pending in the subject application. By this Amendment applicants have canceled claims 1-146 without prejudice and added new claims 147-153. Accordingly, upon entry of this Amendment, claims 147-153 will be pending and under examination.

By this Amendment, applicants have amended the specification to recite the continuing data for the above-identified application. The specification has also been amended to include the reference to Sequence Identification Numbers (SEQ ID NOS:).

The specification has also been amended on page 64, line 4 of Table 2, to correct an obvious typographical error. The term "human PPY" has been deleted and the term "human PYY" has been inserted therein. Support for this amendment may be found inter alia in the specification, as originally-filed, on page 57, line 11, which recites, "human PYY ($K_i = 0.62$ nM)".

Jonathan A. Bard, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 7

Furthermore, the specification has been amended to include the appropriate ATCC Accession numbers. Applicants attach hereto as **Exhibit C** a copy of the ATCC Budapest Treaty Deposit Receipt for plasmid pcEXV-rY4, cell line N-hY4-5, and cell line L-hY4-3.

Applicants, therefore, maintain that the amendments herein to the specification and the claims do not raise any issue of new matter and respectfully request that this Amendment be entered.

By this Amendment, applicants submit a paper copy and computer readable copy of the nucleotide and/or amino acid sequences disclosed in the application in order to fulfill the requirements of 37 C.F.R. §1.821 through 1.825 in connection with this application. Applicants submit herewith twenty two (22) pages of Sequence Listing, numbered 94-115, in compliance with the requirements of §1.821 through 1.825, attached hereto as **Exhibit A**.

Applicants also submit herewith a formatted Sequence Listing in a computer readable form which complies with the requirements of 37 C.F.R. §1.824. In addition, applicants submit a Statement in Accordance with 37 C.F.R. §1.821(f), attached hereto as **Exhibit B**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which is submitted as "Sequence Listing".

Applicants maintain that new claims 147-153 raise no issue of new matter. Support for new claim 147 may be found inter alia in the specification, as originally-filed, at page 5, lines 25-32; page 10, lines 24-34; and page 21, line 8 through page 22, line 11. Support for new claim 148 may be found inter alia in the specification, as originally-filed, at page 6, lines 17-23; and page 25, lines 19-37.